Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Allogeneic hematopoietic stem cell transplantation in Tunisia

Abstract

In 1998, the Tunisian team of the ‘Centre National de Greffe de Moelle Osseuse’ initiated allogeneic hematopoietic SCT (AHSCT) in Tunisia. As of June 2007, information was collected about 299 patients with a first AHSCT and 12 additional retransplants. The median age was 19 years (range 2–49 years). The main indications were aplastic anemia (n=106, 36%), leukemia and nonmalignant disorders (n=153, 51%), Fanconi anemia (n=26, 9%) and other nonmalignant disorders (n=14, 4%). Preparative regimens depended on indication. All donors were HLA geno-identical. The stem cell sources were BM (87%) and PBSCs (13%). At the time of analysis, 200 patients (67%) were alive after a median follow-up of 42 months (range 3–112 months). The overall TRM rate was 17%. Outcome depended on indication. According to our results, allogeneic HSCT is potentially curative for hematological diseases, but it is a toxic approach for malignant disorders.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Thomas ED . Bone marrow transplantation: a review. Semin Hematol 1999; 36: 95–103.

    CAS  PubMed  Google Scholar 

  2. Horowitz M . Uses and growth of hematopoietic cell transplantation. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation. Blackwell Scientific Publishers Inc.: London, New York, 2004, pp 9–15.

    Google Scholar 

  3. Gratwoh A, Baldoremo H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D, for the Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and The European Group for Blood and Marrow Transplantation EBMT (JACIE). Results of the EBMT activity survey 2005 on haematopoietic stem ell transplantation; focus on increasing use of unrelated donors. Bone Marrow Transplant 2007; 39: 71–87.

    Article  Google Scholar 

  4. Schmitz N, Gratwohl A, Golman JM . Allogeneic and autologous transplantation for haematologic diseases, solid tumours and immune disorders: current practice in Europe in 1996 and proposals for an operational classification. Bone Marrow transplant 1996; 17: 471–477.

    CAS  PubMed  Google Scholar 

  5. Torjemane L, Ladeb S, Ben Othman T, Abdelkefi A, Lakhal A, Ben Abdeladhim A . Bone marrow transplantation from matched related donors for patients with Fanconi anaemia using low-dose busulfan and cyclophosphamide as conditioning. Pediatr Blood Cancer 2006; 46: 496–500.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to T Ben Othman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ben Othman, T., Torjemane, L., Abdelkefi, A. et al. Allogeneic hematopoietic stem cell transplantation in Tunisia. Bone Marrow Transplant 42 (Suppl 1), S139–S141 (2008). https://doi.org/10.1038/bmt.2008.143

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.143

Keywords

This article is cited by

Search

Quick links